Amphastar Pharma (AMPH) Tops Q1 EPS by 26c

Amphastar Pharma (NASDAQ: AMPH) reported Q1 EPS of $1.04, $0.26 better than the analyst estimate of $0.78. Revenue for the quarter came in at $171.8 million versus the consensus estimate of $176.36 million.

For earnings history and earnings-related data on Amphastar Pharma (AMPH) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Birchtech Corp. (BCHT) Misses Q2 EPS by 7c
• Eikon Therapeutics, Inc. (EIKN) Misses Q2 EPS by 163c